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Abstract
The implementation of immunotherapy has radically changed the treatment of oncological patients. Currently, immuno-
therapy is indicated in the treatment of patients with head and neck tumors, melanoma, lung cancer, bladder tumors, colon 
cancer, cervical cancer, breast cancer, Merkel cell carcinoma, liver cancer, leukemia and lymphomas. However, its efficacy 
is restricted to a limited number of cases. The challenge is, therefore, to identify which subset of patients would benefit from 
immunotherapy. To this end, the establishment of immunotherapy response criteria and predictive and prognostic biomarkers 
is of paramount interest. In this report, a group of experts of the Spanish Society of Medical Oncology (SEOM), the Spanish 
Society of Medical Radiology (SERAM), and Spanish Society of Nuclear Medicine and Molecular Imaging (SEMNIM) 
provide an up-to-date review and a consensus guide on these issues.
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Immunotherapy clinical application
The implementation of immunotherapy has radically 
changed the treatment of oncological patients. Unlike other 
oncological treatments (such as chemotherapy, tyrosine 
kinase inhibitors and others that act directly upon tumor 
cells), immunotherapy exerts antitumor action by activat-
ing the patient’s immunologic response against cancer and 
can be used as a monotherapy or in combination with other 
immunotherapeutic agents, chemotherapy or targeted thera-
pies [1–6]. Currently, immunotherapy is approved or under 
development for the treatment of patients with head and neck 
tumors, melanoma, lung cancer, bladder tumors, colon can-
cer, cervical cancer, breast cancer, Merkel cell carcinoma, 
liver cancer, leukemia and lymphomas (Fig. 1). However, 
its efficacy is restricted to a limited number of cases. The 
challenge is, therefore, to identify which subset of patients 
would benefit from immunotherapy [7]. There are also other 
important areas of research, such as the establishment of L. Leon-Mateos, M. J. Garcia-Velloso and R. García-Figueiras 
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treatment response criteria according to drug mechanisms 
of action and identifying and managing immune-mediated 
toxicities.
A group of experts from the Spanish Society of Medical 
Oncology (SEOM), the Spanish Society of Medical Radiol-
ogy (SERAM), and Spanish Society of Nuclear Medicine 
and Molecular Imaging (SEMNIM), selected and supported 
by these scientific societies, met to discuss and provide an 
up-to-date introductory review on some general issues on 
immunotherapy, and a multidisciplinary consensus on the 
immunotherapy response criteria and the predictive and 
prognostic biomarkers. In addition, functional and molecular 
imaging advances for immunotherapy response assessment 
are also reviewed. The consensus was initiated with a face-
to-face meeting, where the content, procedures and topic 
distribution among the experts were made. The first draft of 
the consensus was distributed among all participants who 
made comments and amendments to the document that were 
discussed via e-mail and teleconference. The coordinators of 
the consensus agreed a second draft based on the comments 
received. This process was repeated twice until a final draft 
was circulated, agreed and approved by all authors.
Immunotherapy types and mechanisms 
of action
Immunotherapy is a general term comprising several strate-
gies for triggering the host immune response, including the 
following:
Fig. 1  Mechanism of action of immunotherapy and main general 
indications. a The T lymphocyte recognizes the antigen presented 
by the major histocompatibility complex (MHC) of the tumor cell. 
The ligands PD-L1 and PD-L2 function as negative regulators of 
the immune response by binding to the lymphocyte receptor PD-1. 
The anti-PD-1 and anti-PD-L1 antibodies interfere with this bind-
ing, potentiating the immune response against the tumor. b CTLA-4 
is another receptor that inhibits the action of T lymphocytes. The 
monoclonal antibody ipilimumab blocks CTLA-4 and potentiates the 
activity of T lymphocytes. c Several modalities of immunotherapy are 
approved or in development for use in different tumor locations
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1. Checkpoint inhibitors. The immune response involves 
complex signal balances between T lymphocyte cyto-
toxic activation and inhibition [8]. Checkpoint inhibitors 
induce a positive balance that favors the activation of 
effector T lymphocytes.
2. Cytokines. Cytokines (interferon α/β, interleukin 12, 
etc.) facilitate adequate lymphocyte activation. Although 
their clinical use is limited by their marked toxicity, 
some cytokines, such as interleukin 2 or alpha 2b inter-
feron, have shown results for treating melanoma and 
renal cell carcinoma [9].
3. Innate immunity activation. Nonspecific initial immune 
response activation might also facilitate cancer pro-
gression management. One example could be adjuvant 
treatment of urothelial carcinoma with Calmette-Guérin 
bacillus (BCG) [10].
4. Cell therapy. Different strategies consist of manipulating 
patient cells to restore their capacity to recognize and 
kill tumor cells.
4.1 Tumor-Infiltrating Lymphocytes (TILs): TIL iso-
lates are taken from tumor biopsies and replicated in 
ex vivo cell culture for their later infusion in patients 
previously submitted to myeloablative treatments 
[11].
4.2 Chimeric antigen receptor (CAR) - T cells: patient’s 
T lymphocytes are extracted by leukapheresis and 
genetically modified ex vivo to recognize a given 
Fig. 2  Pesudoprogression in a patient with lung adenocarcinoma. 
Patient diagnosed in January 2014 of well-differentiated lung adeno-
carcinoma T4N3M0 stage, and treated with cisplatin and pemetrexed. 
Progression resistant to a second-line chemotherapy was detected in 
April 2016. 18F-FDG PET/CT (a) identified  a lesion located in LII 
(SUVmax of 12.5) and mediastinal and hilar lymph node uptake 
(SUVmax of 3). Nivolumab was started and  an18F-FDG PET/
CT  study 2016 was performed for response assessment in June (b) 
revealing  an increase in the metabolism and size of the lung lesion 
(SUVmax of 14.4) and in the number and metabolism of thoracic 
lymph nodes (SUVmax of 4.9). Because of clinical stability,  immu-
notherapy was maintained  and18F-FDG PET/CT performed in August 
2016 (c) showed a metabolic reduction of lung lesion (SUVmax of 
2.4) and lymph nodes  (SUVmax of 2.6), consistent with partial 
response. Given the evolution, the 18F-FDG PET/CT(B) was inter-
preted as pseudoprogression
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preselected antigen. Such therapy has shown 
remarkable activity against hematological neo-
plasms [12].
5. Oncolytic viruses. human viruses have been genetically 
modified to infect and kill tumor cells, creating a pro-
inflammatory microenvironment triggering additional 
adaptive immune mechanisms [13].
6. Vaccines. specific antitumor response activation can be 
elicited by active immunization (vaccine administration) 
derived from cancer cell expressions of certain tumor-
specific antigens.
Unusual response patterns associated 
with immunotherapy
Tumor response to oncologic treatments has been associ-
ated with tumor size reduction. However, immunotherapy 
may usually cause several atypical response patterns, such 
pseudoprogression, hyperprogression, and dissociated 
responses, that are difficult to evaluate according to classic 
tumor response criteria and with conventional imaging tech-
niques. Besides, immunotherapy may also achieve durable 
responses in a subset of patients with advanced cancer that 
can be maintained even after stopping treatment.
Sustained responses
Sustained responses are one of the main response patterns 
associated with immunotherapy. A major breakthrough of 
immunotherapy is its potential to achieve lasting responses 
in a subset of patients with advanced cancer that can be 
maintained even after stopping treatment. There is no stand-
ard definition of sustained response in the literature. This 
kind of response appears in all cancer types, and there are 
current investigations underway to identify predictive factors 
of this feature [14–16].
Pseudoprogression
Tumor shrinkage has been identified after an initial increase 
in tumor burden or the appearance of new lesions. This phe-
nomenon, called pseudoprogression, is the consequence 
of treatment-activated immune cells infiltrating the tumor 
milieu. It is associated with edema or necrosis that may 
cause a radiographic increase in tumor volume, including 
the appearance of lesions not recognized on previous imag-
ing [17, 18]. Pseudoprogression is the most characteristic 
atypical response pattern associated with immunotherapy. 
It was first reported in melanoma patients treated with anti-
CTLA4, but this response pattern may also appear with 
other immunotherapy agents and in different tumor types 
(Fig. 2) [19–21]. Pseudoprogression can appear early dur-
ing treatment (within the first 12 weeks of therapy) but can 
also be a late phenomenon. A recent study in melanoma 
patients showed an early pseudoprogression rate of 4.6% 
and a late pseudoprogression rate of 2.8% [20]. There is 
a variable pseudoprogression rate among different tumor 
types. The rate is higher in the case of melanoma (up to 
10% of patients) [22] and lower in epithelial malignancies 
such as lung cancer and urothelial carcinoma (1.5–3.0%). 
In this setting, we should consider that most of the cases of 
possible pseudoprogression reflect real progression. How-
ever, there is a need to establish specific response criteria for 
immunotherapy allowing for the continuation of treatment 
after apparent progression, according to classic criteria in 
clinically fit patients without associated toxicity.
Hyperprogression
Hyperprogression is defined as tumor growth after the ini-
tiation of immunotherapy that is faster than under previous 
treatment and has been described based on retrospective 
observations [23]. The rate of hyperprogression is variable, 
ranging from 4 to 29% for different agents and tumor types 
[24]. Hyperprogression is prone to controversies and shows 
considerable incidence variability due to clinical trial het-
erogeneity. It is difficult to establish a difference between 
hyperprogression as an independent entity and rapid pro-
gression already observed in oncologic patients. Different 
papers published have defined multiple parameters to assess 
and define hyperprogression, such as the “tumor growth rate 
(TGR)” and the “time-to-treatment failure (TTF)”. These 
parameters usually combine Response Evaluation Criteria in 
Solid Tumors (RECIST) and elapsed time between assess-
ments [25].
Hyperprogression correlates with worse patient survival 
rates. Several studies have been conducted to identify hyper-
progression risk factors, including advanced age, multiple 
metastatic lesions, and previous radiotherapy [23, 26, 27].
Dissociated response
A dissociated response is considered when there is regres-
sion in some target lesions but progression in others. In this 
scenario, it would be important to identify patients with oli-
goprogression, due to the possibility of treating these lesions 
locally. This pattern has already been described in the con-
text of conventional chemotherapy and especially in the case 
of targeted therapies. A study including lung cancer patients 
treated with immunotherapy described a 7% rate of dissoci-
ated response [21]. In this study, patients with pseudopro-
gression or dissociated response showed better survival.
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Key points and recommendations
Novel patterns of response and progression to immunother-
apy, which may be more frequent in immunotherapy than in 
chemotherapy or targeted therapies, should be known.
Immune‑related adverse events
Apart from these atypical response patterns, immune-
related toxicities may appear during treatment due to self-
immunity deregulation or induction. The most common 
adverse event is dermatologic toxicity, but immune-related 
toxicity could affect any organ and cause different clinical 
and radiological manifestations that might mimic tumor 
progression (Table 1) [28]. These adverse events must be 
identified to initiate immunosuppression treatment. Pneu-
monitis is the most common thoracic complication, with 
different radiologic manifestations [29]. A nodular pattern 
of organized pneumonia or sarcoidosis/sarcoid reaction 
could be confounded with disease progression. To differ-
entiate these adverse events from progression, it is impor-
tant to ascertain whether there is only thoracic progression 
and to compare the initial tumor radiological character-
istics with the current tumor manifestations [30]. Other 
toxicities with doubtful radiologic or metabolic manifesta-
tions that could be confounded with progression are pitui-
tary gland disorders, thyroiditis, pericarditis, colitis and 
pancreatitis, all characterized by volume augmentation of 
the different organs and increased [18F]fluorodeoxyglu-
cose (18F-FDG) uptake in positron emission tomography 
(PET) [31, 32].
Key points and recommendations
• The main clinical and imaging manifestations of 
immune-related toxicities must be known to make an 
early diagnosis and to initiate early treatment of these 
adverse events.
• FDG-PET is a non-invasive imaging technique that 
allows precise localization of all potential immune-
related adverse effects and to monitor the response to 
immunosuppression treatment.
Immunotherapy response criteria
Tumor therapy response is categorized into four main 
groups: complete response [CR], partial response [PR], 
progressive disease [PD], and stable disease [SD]. Dur-
ing the last decades, several radiologic and metabolic 
response criteria for different oncological treatments have 
been described [33]. The appearance of new therapeutic 
strategies in recent years (targeted therapies, antiangio-
genic agents and, more specifically, immunotherapy) has 
revealed some limitations of these criteria, such as the pos-
sibility of not detecting atypical response patterns (such as 
pseudoprogression) [34]. In this section, we will review 
the different imaging criteria described for the assessment 
of immunotherapy response.
Anatomic response criteria
All radiologic response criteria for immunotherapy share 
common aspects, such as being based on target lesion 
dimension changes (measurable lesions, most representa-
tive of total tumor burden) and nontarget lesions (all the 
other measurable and unmeasurable lesions) defined in base-
line studies. In short, differences among several response 
criteria to assess immunotherapy treatment are based on 
measurement methods (single, if based on RECIST crite-
ria; or bidimensional, if based on the World Health Organi-
zation (WHO) measurements) or on the consideration of 
new lesions (specifically unmeasurable lesions) to define if 
there is progression or not; the criteria also differ in regard 
to incorporating new lesions in the baseline tumor burden 
(Table 2).
The anatomic or radiologic immunotherapy response cri-
teria include the following:
• RECIST 1.1: Version 1.1 of the “conventional” RECIST 
criteria introduced in 2009 are the most frequently used 
criteria for solid tumor treatment response assessment. 
These criteria are the only criteria that have been vali-
dated and accepted by the main regulatory agencies [35–
38]. However, according to RECIST, increased tumor 
Table 1  Main immune-related adverse events in patients treated with 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































 Clinical and Translational Oncology
1 3
size or the appearance of new lesions in a cancer patient 
would invariably imply PD, which would result in an 
incorrect assessment of those patients with pseudopro-
gression, for instance.
• Immune-related response criteria (irRC): The irRC were 
introduced in 2008, and their main contribution was to 
incorporate new measurable lesions into baseline refer-
ence index lesions according to a new concept called 
“total tumor burden”. In addition, unlike the timeline of 
the classic criteria, disease progression should be con-
firmed within 4 weeks. Some limitations of the irRC 
are as follows: (1) Based on the WHO criteria, the irRC 
cannot be compared to the RECIST criteria because of 
the use of bidimensional-type measurements; (2) worse 
assessment of node involvement; and (3) possible over-
estimation of treatment efficacy, because they do not take 
into consideration unmeasurable new lesions [39–41].
• Immune-related RECIST (irRECIST): Developed in 2014 
with the intention of aligning irRC with RECIST 1.1, 
irRECIST simplified immunotherapy response assess-
ment and allowed comparison with other clinical trials 
that used RECIST criteria. According to the irRECIST 
criteria, new measurable lesions are added to baseline 
lesions in a concept called “total tumor burden meas-
ured”. Similar to the irRC criteria, every disease progres-
sion case should be confirmed radiologically within a 
4-week period [42, 43].
• Immune RECIST (iRECIST): These criteria were derived 
from a consensus among the RECIST work group, phar-
maceutical industries, and the main regulatory agencies 
to standardize and validate immunotherapy response cri-
teria. The iRECIST would become a consensus guide-
line assuring consistent data design and collection that 
would facilitate the analysis and compared interpretation 
of immunotherapy-based clinical trials. Unlike the other 
criteria, new lesions were not incorporated into baseline 
lesions, and thus, they were registered separately. One of 
the key concepts of iRECIST is immune-unconfirmed PD 
(iUPD), a category including cases at the first sign of PD 
to be confirmed within the next 4–8 weeks [41, 44, 45].
Immune-modified RECIST (imRECIST). imRECIST was 
described in 2018 and was inspired by the irRC criteria 
principles. New measurable lesions were incorporated 
into baseline target lesions (unlike in iRECIST). The 
imRECIST criteria relate patterns of response or pro-
gression to overall survival through indirect assessment 
criteria (such as progression-free survival) [46].
Key points and recommendations
• Although the classic RECIST criteria remain a useful 
tool to assess response to immunotherapy in the clini-
cal practice, sometimes they underestimate the benefit 
of immunotherapy. Specific immune-related response 
criteria must be considered to evaluate patients under 
treatment with immunotherapy.
Metabolic response criteria
Given the limitations of conventional imaging techniques 
for the assessment of immunotherapy-treated patients, 
new functional and molecular imaging techniques were 
considered.
Metabolic response criteria for solid tumors were pro-
posed, because tumor response to new targeted molecu-
lar therapies in the field of oncology might manifest as 
decreased 18F-FDG uptake without a marked reduction in 
tumor size (Table 3).
• European Organization for Research and Treatment of 
Cancer (EORTC ): The first PET-based criteria were 
proposed in 1999 to assess metabolic response in solid 
tumors [47] and were the first criteria applied to assess 
metabolic response to immunotherapy [48]. A CR is 
defined as a resolution of FDG uptake within the tumor 
that is indistinguishable from the surrounding normal 
tissue. A > 25% increase in tumor standard uptake value 
(SUV) or the appearance of new 18F-FDG-avid lesions 
defines progression.
• PET Response Criteria in Solid Tumors (PERCIST): 
Wahl et al. [49] proposed new response criteria applying 
the average SUV corrected by lean body mass (SUL) 
within a 1-cm3 spherical volume of interest (SULpeak) 
[50]. More than 30% or 0.8-unit increases in SULpeak 
or new 18F-FDG-avid lesions indicated progression.CR 
was defined as 18F-FDG uptake of target lesions lower 
than that of the liver and indistinguishable from the back-
ground.
• PET/CT Criteria for Early Prediction of Response to 
Checkpoint Inhibitor Therapy (PECRIT): Choet et al. 
[51] analyzed different criteria in 20 advanced melanoma 
patients treated with checkpoint inhibitors. They defined 
new morpho-functional early response criteria combin-
ing the change in the sum of RECIST 1.1-based target 
lesion diameters and the PERCIST SULpeak change in 
the hottest lesion, with a 95% diagnostic accuracy (sen-
sitivity 100%, specificity 93%). A very interesting aspect 
of these criteria is the capacity to predict clinical benefit 
at 4 months, defined as RECIST CR, PR or SD based on 
an increase > 15.5% in the SULpeak of the hottest lesion. 
Therefore, the combination of morphologic and meta-
bolic information constitutes the main tool for immuno-
therapy response assessment.
• PET Response Evaluation Criteria for Immunotherapy 
(PERCIMT). A prospective study was conducted recently 
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and included 41 metastatic melanoma patients treated 
with ipilimumab [52]. The authors defined clinical ben-
efit as SD, PR and CR, and to predict outcome, they 
established optimal cut-off points for the number of new 
lesions according to their functional diameter measured 
in fused 18F-FDG PET/CT images. Neither maximum 
SUV (SUVmax) nor mean (SUVmean) changes during 
immunotherapy were correlated with clinical response, 
but they observed that a cut-off of four new lesions was 
predictive of treatment failure.
• Immunotherapy-modified PERCIST (imPERCIST): 
Described in 2019, these criteria do not necessarily con-
sider new lesions as disease progression, as opposed to 
the PERCIST criteria. New lesions are included in 18F-
FDG tumor uptake quantification, and progression is 
defined as an increase > 30% in the sum of the SULpeak 
of up to 5 lesions from baseline and follow-up PET with 
a maximum of 2 lesions per organ [53]. In this setting, Ito 
et al. [53] analyzed the relationship between tumor 18F-
FDG uptake changes and survival in melanoma patients 
treated with ipilimumab according to both the PERCIST 
standard criteria and the new imPERCIST criteria. The 
authors concluded that PERCIST-based tumor response 
criteria correlated significantly with overall survival, and 
the new imPERCIST criteria improved this correlation 
as well as the prognostic value of 18F-FDG PET/CTcom-
pared to the results obtained using PERCIST.
Key points and recommendations
• FDG PET should be performed before immunotherapy 
(for evaluating the whole metabolic tumour burden), after 
2–3 cycles of immunotherapy, and at the end of treat-
ment (for response assessment). New PET-based criteria 
must be introduced in clinical practice. These criteria 
should be used instead of PET Response Criteria in Solid 
Tumors (PERCIST), which do not enable progression 
disease to be distinguished from the atypical response 
patterns to immunotherapy. imPERCIST criteria may 
improve the prediction of overall survival and the assess-
ment of response in patients treated with immunotherapy, 
and PERCIMT or PECRIT may identify patients who 
achieve clinical benefit from immune treatment, defined 
as complete response, partial response or stable disease.
Predictive and prognostic biomarkers
One of the main clinical concerns related to immunotherapy 
is the identification of biomarkers allowing for the selec-
tion of patients who would respond to the therapy or for the 
prediction of atypical responses such as pseudoprogression 
or hyperprogression. Different types of biomarkers have 
been proposed, including PD-L1 expression, microsatellite 
instability, tumor mutational burden, T lymphocyte tumor 
infiltration or imaging tests.
Serum/tissue biomarkers
Immune checkpoint inhibitors constitute the main immu-
notherapy treatment in clinical practice. Some biomarkers 
have been proposed allowing the identification of patient 
groups who would benefit more from PD-1/PD-L1 inhibitors 
than from other therapeutic options. Without a doubt, the 
best-known biomarker is PD-L1 expression in tumor cells 
[54] or in immunologic system cells [55]. The usefulness of 
this marker is low in general, because we frequently observe 
patients who do not express PD-L1 and nevertheless respond 
to the treatment, and vice versa, and even in some studies, 
a greater response has been described in patients with low-
PD-L1-expression tumor cells [56, 57]. However, more than 
50% PD-L1 tumor cell expression in non small cell lung can-
cer patients predicts higher effectiveness of pembrolizumab 
as a first-line treatment compared to the effectiveness of 
chemotherapy. Furthermore, PD-L1 expression is required 
by regulatory agencies like EMA to prescribe atezolizumab 
(PD-L1 > 5%) or pembrolizumab (PD-L1 > 10%) as a first-
line treatment for urothelial cancer patients who are not can-
didates for chemotherapy with cisplatinum.
Nevertheless, the most relevant biomarker is microsatel-
lite instability (observed in patients with DNA repair path-
way alterations) and predicts a very high response rate to 
PD-1 /PDL-1 inhibitors [58]. This is why regulatory agen-
cies have approved pembrolizumab for treating patients with 
tumors showing microsatellite instability, independent of 
their histological type. Finally, high tumor mutational bur-
den has been linked to the effectiveness of immunotherapy 
[59], but given the conflicting results among several studies 
this biomarker has not yet been implanted in the clinic nor 
authorized by regulatory agencies.
Regarding biomarkers for monitoring disease progres-
sion, we would like to note that the interleukin-8 serum level 
directly correlates with tumor burden and that variations in 
interleukin-8 during treatment with PD-1/PD-L1 inhibitors 
are associated with clinical response [60]. This type of bio-
marker could be useful for determining treatment effective-
ness in conjunction with imaging tests, especially in cases 
of difficult response assessment, such as pseudoprogression.
Key points and recommendations
• Treatment with PD-1 / PD-L1 blockade should be pre-
scribed based on biomarker expression in the following 
clinical situations:
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  Metastatic non-small cell lung cancer and meta-
static bladder cancer: monotherapy with immune 
checkpoints inhibitors is restricted to patients with 
positive expression of PD-L1 tumor cells (TPS) or a 
composite positive score (CPS).
Pembroliuzmab is approved by the FDA for the treat-
ment of adult and pediatric patients with unresectable 
or metastatic, microsatellite instability-high (MSI-H) 
or mismatch repair deficient (dMMR) solid tumors that 
have progressed following prior treatment and who 
have no satisfactory alternative treatment options, and 
for the treatment of unresectable or metastatic MSI-H 
or dMMR colorectal cancer that has progressed fol-
lowing treatment with chemotherapy.
Radiological biomarkers
Several radiological findings derived from conventional 
imaging techniques might predict or suggest a response to 
immunotherapy. Thus, regardless of the classic criterion of 
size reduction, the halo sign can identify treatment response 
in patients with pulmonary metastases of melanoma under-
going treatment with immunotherapy [61]. Lesion density 
changes in computerized tomography (CT) have been con-
sidered as response criteria for other types of therapies. In 
this setting, Gray et al. evaluated melanoma patients treated 
with interferon and antiangiogenic therapy based on the 
morphology, attenuation, size, and structure (MASS) cri-
teria, showing that they could predict progression-free sur-
vival and overall survival. Finally, new contrast media, such 
as ultrasmall superparamagnetic ironoxide (USPIO), tend 
to accumulate in tumor-associated macrophages and might 
be used for assessing immune cell infiltration levels in the 
tumor to evaluate possible immunotherapy responses by 
magnetic resonance imaging (MRI) [62].
Artificial intelligence has improved the analysis of medi-
cal images [63]. Radiomics, a method that extracts multiple 
quantitative data points from medical images, would allow 
the development of imaging biomarkers. Some image find-
ings have been correlated with PD-L1 or IDO1 expression 
[63] or with the degree of tumor-infiltrating lymphocytes 
[64–66]. Chen et al. [66], by combining clinical and radi-
omic data extracted from the texture and morphological 
analysis of magnetic resonance images with hepatic-specific 
contrasts, could predict lymphocytic tumor-infiltration levels 
in hepatocellular carcinomas, and they found that tumors 
with higher lymphocyte infiltration were more homogene-
ous. Several parameters obtained from radiomic analysis of 
CT images were also correlated with clinical evolution after 
anti-PD-1 or PD-L1 therapies in patients with lung cancer 
[65, 67–70] or head and neck cancer [71].
Radiomics analysis of tumor structure, texture and het-
erogeneity might facilitate the obtainment of more accurate 
information on tumor biology. Radiomics could also be use-
ful for assessing atypical responses and toxicities associated 
with immunotherapy. In this way, Tunali et al. [72] devel-
oped clinical radiological models able to predict possible 
hyperprogression and define poorer survival rates in patients 
treated with immunotherapy, and Colen et al. [73] estab-
lished a radiomics-based model to predict immunotherapy-
induced pneumonitis.
Functional imaging techniques have rarely been used as 
immunotherapy biomarkers. Nevertheless, whole-body MRI 
with diffusion-weighted sequences has been used for assess-
ing rituximab-treated lymphoma patients, evidencing that 
apparent diffusion coefficient changes (ADCs) may allow the 
differentiation of responding from nonresponding patients 
[74, 75] and confirm an early response.
Metabolic and molecular imaging biomarkers
PET imaging techniques offer qualified imaging biomarkers 
that can be used not only as predictors of therapy response 
but also as prognostic factors. The most frequently used 
markers are SUV and new quantitative indexes, such as 
metabolic tumor volume (MTV) and total lesion glycolysis 
(TLG). Bastiannet et al. [76] correlated SUV in melanoma-
infiltrated lymph nodes with prognosis in patients with 
stage III melanoma, showing a significantly higher 5-year 
rate with lower (41%) than with higher (24%) SUVmean. 
However, other authors could not confirm this correlation 
between glucose uptake in PET and survival.
MTV defines the tumor volume (in cm3) by pathologic 
18F-FDG uptake, and TLG is calculated by multiplying 
MTV by SUVmean, which weights the volumetric bur-
den and metabolic activity of tumors. These biomarkers 
have demonstrated prognostic value in different solid and 
hematologic neoplastic tumors. Ito et al. [77] evaluated a 
cohort of 142 consecutive melanoma patients treated with 
ipilimumab, and MTV was an independent prognostic factor 
for overall survival (p = 0.001). Thus, patients with higher 
MTV showed lower survival than patients with below-aver-
age MTV (10.8 months versus 26 months, respectively). On 
the other hand, the combination of metabolic biomarkers 
with clinical prognostic factors such as age, LDL and brain 
metastasis allowed patient stratification into significantly dif-
ferent overall survival ranges.
18F-FDG PET radiomic analysis of tumors might pro-
vide more accurate information on tumor biology. The most 
commonly used parameters are those expressing 18F-FDG 
tumor metabolic heterogeneity, which has been correlated 
with higher relapse rates and has shown prognostic value 
for different tumor types [78]. A retrospective study con-
ducted with patients with metastatic melanoma showed great 
metabolic heterogeneity in the metastasis of each patient and 
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among patients. A higher 18F-FDG uptake showed a rela-
tionship with the lactate dehydrogenase (LDH) values [79]. 
Finally, a recent study showed better clinical outcome in 
colon cancer patients with higher tumor sphericity and lower 
tumor volume and 18F-FDG heterogeneity on PET [80].
Key points and recommendations
• Apart of different molecular markers (PD-L1 expres-
sion, microsatellite instability, and mismatch repair defi-
ciency), there are emerging imaging-based biomarkers 
to predict and evaluate response to immunotherapy and 
the risk of immune-related adverse events. However, its 
usefulness in the clinical practice is still limited.
Functional and molecular imaging advances 
for immunotherapy response assessment
In preclinical models, multiparametric MRI (including con-
trast T2-, ADC- and T1-weighted imaging) has been used in 
glioblastoma multiforme brain tumors for an early response 
assessment of CAR-T and natural killer (NK) cell therapy 
[81, 82]. Promising techniques such as 19F MRI might facil-
itate in vivo assessment of monocytes and macrophages. 
The clinical use of functional imaging techniques has been 
limited in the assessment of immunotherapy response. The 
value of MRI diffusion has been demonstrated in lymphoma 
patients [74, 75, 83, 84], and CT perfusion has been applied 
for response assessment of interferon 1-treated metastatic 
renal cancer and carcinoid tumors [85, 86].Functional 
imaging techniques might also facilitate the differentiation 
between tumors and inflammatory sites in glioblastoma 
patients treated with dendritic cell immunotherapy [87].
On the other hand, immunoPET with specific labeled 
antibodies has great potential when the therapy depends on 
tumor target expression in lesions and enables assessment 
of biomarker expression evolution over time. Most immun-
oPET studies are preclinical or in the framework of clinical 
trials. 68 Ga-Granzyme B PET quantification is a highly 
sensitive and specific early predictor of therapeutic efficacy 
of checkpoint inhibitor therapy [88]. In non-small cell lung 
cancer patients, immunoPET with 89Zr-nivolumab enabled 
the noninvasive quantification of PD-1/ PD-L1 tumor expres-
sion, demonstrating PD-L1 tumor expression heterogeneity 
between metastases of the same patient and among differ-
ent patients [89]. In addition, PD-1 tumor expression was 
observed with 18F-BMS-986192 in patients with low PD-L1 
expression, as determined by immunohistochemistry, most 
likely due to tumor PD-L1 expression heterogeneity. There-
fore, immunoPET might identify patients despite low PD-L1 
expression in biopsies, assessing tumor microenvironment 
changes induced by treatment with predictive and prognostic 
value. In a study conducted with 89Zr-atezolizumab in lung, 
bladder and breast cancer patients, PET uptake exhibited 
high predictive value concerning treatment response and a 
strong correlation with survival [90].
Despite the promising data obtained by functional and 
molecular imaging techniques, clinical studies are neces-
saryto confirm these preliminary findings.
Key points and recommendations
• In the future, immunoPET imaging, which offers new 
radioactive tracers that target key immune pathways and 
cellular immune responses, should be used to improve 
patient´s stratification, to predict the efficacy of immu-
notherapy, and to assess tumor response.
• Functional imaging techniques, including quantitative 
parameters derived from diffusion-weighted or perfusion 
imaging, have demonstrated a limited role in the assess-
ment of immunotherapy. Nowadays, their clinical use 
would not be recommended beyond the research field.
Conclusions
Cancer immunotherapy has led to a significant breakthrough 
in patients’ outcomes. In this setting, both conventional 
imaging techniques and classic response criteria have shown 
limited applicability for the assessment of immunotherapy 
response. To overcome these limitations, there is a growing 
need to maximize our ability to image the biological fea-
tures associated with the interactions between tumors and 
the immune system. The combination of morphological and 
functional and/or metabolic response criteria together with 
the emergence of radiomics offers new approaches for the 
development of prognostic and predictive imaging biomark-
ers for immunotherapy response assessment.
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